Executive Brief

News Report

The News: WHO updates treatment guidelines for plaque psoriasis, highlighting biologics and biosimilars.
Clinical Win: Enhanced access to effective therapies for plaque psoriasis through updated guidelines.
Target Specialty: Dermatology

Key Data at a Glance

Estimated global prevalence of plaque psoriasis: 2-3%
Percentage reduction in treatment costs with biosimilars: approximately 60%

The World Health Organization (WHO) has published updated guidelines on the treatment of plaque psoriasis, emphasizing the role of biologics and biosimilars in management strategies as of 2025. This update is crucial for healthcare professionals as it reflects the evolving landscape of treatment options available for patients suffering from this chronic skin condition.

Clinical Context

Plaque psoriasis is a chronic autoimmune condition characterized by the rapid proliferation of skin cells, leading to thick, red, scaly patches. It affects approximately 2-3% of the global population and can significantly impact quality of life due to physical discomfort and psychological distress. Current treatment options range from topical therapies to systemic treatments, including biologics that target specific pathways in the immune response. Traditional systemic therapies, such as methotrexate, have been widely used but come with significant side effects. The advent of biologics, particularly those targeting interleukin (IL)-17 and IL-23 pathways, has transformed the management of moderate to severe plaque psoriasis, offering enhanced efficacy and improved safety profiles. The introduction of biosimilars has further expanded access to these advanced therapies, particularly in low- and middle-income countries where treatment costs can be prohibitive.

Key Findings

The updated WHO guidelines emphasize the effectiveness of IL-17 and IL-23 inhibitors, such as bimekizumab and guselkumab, in achieving significant skin clearance in patients with moderate to severe plaque psoriasis [1].

Biosimilars are now recognized as essential to expanding access to biologic therapies, providing a cost-effective alternative that maintains therapeutic equivalence to their reference products [4].

The guidelines recommend considering patient-specific factors, including comorbidities and treatment history, when selecting a biologic or biosimilar therapy [2].

The introduction of oral therapies, such as deucravacitinib, offers an alternative for patients who prefer non-injection options, with evidence supporting its efficacy in achieving clear skin [8].

What This Means for Clinical Practice

The updated WHO guidelines on plaque psoriasis treatment underscore the importance of personalized medicine in dermatology. Clinicians should assess individual patient needs, including their treatment preferences and potential comorbidities, when selecting among the available biologics, biosimilars, and oral therapies. The inclusion of biosimilars in treatment protocols will help improve patient access to effective therapies, particularly in resource-limited settings. As new treatments continue to emerge, ongoing education and adaptation of clinical practices will be necessary to optimize patient outcomes in plaque psoriasis management. The question remains: how will these evolving treatment options be integrated into existing clinical workflows and insurance reimbursement strategies?

Clinical Perspective

Workflow: Clinicians should integrate the latest guidelines into practice by evaluating patient-specific factors when prescribing treatments.

Economics: The introduction of biosimilars will significantly reduce treatment costs, improving access for patients in need.

Patient Outcomes: Personalized treatment approaches are expected to enhance patient satisfaction and clinical outcomes in plaque psoriasis management.

Dr. Divya Agarwal, Dermatology

Biosimilars and Biologics for Plaque Psoriasis: 2025 Treatment Landscape

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Dermatology in your inbox.

Related Drug Updates

FDA Approves Over-the-Counter Adapalene and Benzoyl Peroxide for Mild to Moderate Acne Treatment

FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasis: Oral IL-23 Antagonist Launches New Treatment Option

Atopic Dermatitis Biologics Comparison: Dupilumab, Tralokinumab, Lebrikizumab, and JAK Inhibitors

Verified HCP Portal